ABBV vs DE: Which Is the Better Buy?
Side-by-side comparison of AbbVie Inc. and Deere & Company — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-09-23.
AbbVie Inc. · Healthcare
$261.70
-1.0% upside to fair value
Med Conviction
Grade C
High Quality
VS
Deere & Company · Industrials
$703.12
-12.2% upside to fair value
Med Conviction
Grade C
High Quality
QuantHub Verdict
ABBV has more upside to fair value
(-1.0%).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
ABBV |
DE |
| Current Price |
$261.70 |
$703.12 |
| Fair Value Estimate |
$259.04 |
$616.99 |
| Upside to Fair Value |
-1.0%
|
-12.2%
|
| Market Cap |
$462.4B |
$189.8B |
| Forward P/E |
—
|
—
|
| EV / EBITDA |
24.8x
|
22.1x
|
| Price / Sales |
7.2x
|
4.0x
|
| Price / FCF |
23.6x
|
49.1x
|
| Revenue Growth YoY |
+10.2%
|
+7.0%
|
| Gross Margin |
71.5%
|
35.7%
|
| Operating Margin |
29.3%
|
19.0%
|
| Return on Equity |
-136.5%
|
18.1%
|
| Dividend Yield |
2.61% |
0.92% |
| FCF Yield |
4.25%
|
2.04%
|
| Analyst Consensus |
Strong Buy
|
Buy
|
Investment Thesis
AbbVie is a diversified branded-biopharma company spanning immunology, neuroscience, oncology and aesthetics, with high-margin TTM economics including a 71.5% gross margin and 29.3% operating margin. Its successor immunology franchises are performing strongly: Q2 2026 revenue rose 10.2% year over year, with Skyrizi up 24.4% to $5.505 billion and Rinvoq up 24.5% to $2.525 billion, helping offset a…
Deere & Company is a 1837-founded global manufacturer of agricultural, turf, and construction equipment organized across Production and Precision Agriculture, Small Agriculture and Turf, Construction and Forestry, and Financial Services, employing roughly 73,100 people under CEO John C. May. Business quality is high on franchise strength but currently strained by the large-agriculture cycle: TTM …
Accumulation Zones
| Metric |
ABBV |
DE |
| Zone Low |
$194.28 |
$462.74 |
| Zone High |
$220.18 |
$524.44 |
| In Buy Zone? |
No
|
No
|